Reports Q4 revenue $51.1M, consensus $51.41M. "We are proud that KIMMTRAK, the world’s first commercialized TCR therapy, has been approved in over 30 countries for patients with metastatic uveal melanoma. In 2023, we will make it available to even more patients with launches planned in additional countries and through enrollment of cutaneous melanoma patients into our registrational tebentafusp trial," said Bahija Jallal, Chief Executive Officer of Immunocore. "We are also focused on progressing our PRAME clinical programs with ongoing expansion arms in multiple tumor types. Our platform continues to deliver first-in-class oncology programs, like PIWIL1, and several infectious disease candidates."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMCR:
- Immunocore Reports 2022 Financial Results and Provides Business Update
- Immunocore to present at upcoming investor conferences
- Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
- Immunocore to participate in a conference call with H.C. Wainwright
- Immunocore announces initial Phase 1 data for IMC-M113V